Publications

Characterization of the posttranscriptional modifications in Legionella pneumophila small-subunit ribosomal RNA.

• Emmerechts G, Maes L, Herdewijn P, Anné J, Rozenski J.
  Chem Biodivers. 2008 Dec;5(12):2640-53.

Intragenic tandem repeat variation between Legionella pneumophila strains.

• Coil DA, Vandersmissen L, Ginevra C, Jarraud S, Lammertyn E, Anne J.
  BMC Microbiol. 2008 Dec 10;8(1):218.

The importance of the twin-arginine translocation pathway for bacterial virulence.

• De Buck E, Lammertyn E, Anné J.
  Trends Microbiol. 2008 Sep;16(9):442-53

Characterization of the Streptomyces lividans PspA response.

• Vrancken K, Van Mellaert L, Anné J.
  J Bacteriol. 2008 May;190(10):3475-81

Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems. Genet

• Wei MQ, Ren R, Good D, Anné J.
  Vaccines Ther. 2008 Feb 17;6:8.

A faster and more accurate assay for intracellular replication of Legionella pneumophila in amoebae hosts. J

• Coil DA, Anné J, Lammertyn E.
  Microbiol Methods. 2008 Feb;72(2):214-6

Abstract The role of protein secretion systems in the virulence of the intracellular pathogen Legionella pneumophila.

• De Buck E, Anné J, Lammertyn E.
  Microbiology. 2007 Dec;153(Pt 12):3948-53. Review.

Legionella pneumophila exhibits plasminogen activator activity.

• Vranckx L, De Buck E, Anné J, Lammertyn E.
  Microbiology. 2007 Nov;153(Pt 11):3757-65.

Evidence for the Presence of Legionella Bacteriophages in Environmental Water Samples.

• Lammertyn E, Vande Voorde J, Meyen E, Maes L, Mast J, Anné J.
  Microb Ecol. 2007 Oct 24

Differential 2-D protein gel electrophoresis analysis of Legionella pneumophila wild type and Tat secretion mutants.

• De Buck E, Höper D, Lammertyn E, Hecker M, Anné J.
  Int J Med Microbiol. 2007 Aug 25

Recombinant production of Streptococcus equisimilis streptokinase by Streptomyces lividans.

• Pimienta E, Ayala JC, Rodríguez C, Ramos A, Van Mellaert L, Vallín C, Anné J.
  Microb Cell Fact. 2007 Jul 5;6:20.

Post-transcriptional modification mapping in the Clostridium acetobutylicum 16S rRNA by mass spectrometry and reverse transcriptase assays.

• Emmerechts G, Barbé S, Herdewijn P, Anné J, Rozenski J.
  Nucleic Acids Res. 2007;35(10):3494-503.

The Tat pathway in Streptomyces lividans: interaction of Tat subunits and their role in translocation.

• De Keersmaeker S, Vrancken K, Van Mellaert L, Anné J, Geukens N.
  Microbiology. 2007 Apr;153(Pt 4):1087-94.

The twin-arginine translocation pathway is necessary for correct membrane insertion of the Rieske Fe/S protein in Legionella pneumophila.

• De Buck E, Vranckx L, Meyen E, Maes L, Vandersmissen L, Anné J, Lammertyn E.
  FEBS Lett. 2007 Jan 23;581(2):259-64.

pspA overexpression in Streptomyces lividans improves both Sec- and Tat-dependent protein secretion.

• Vrancken K, De Keersmaeker S, Geukens N, Lammertyn E, Anné J, Van Mellaert L.
  Appl Microbiol Biotechnol. 2007 Jan;73(5):1150-7.

Effect of iron on the expression of sirR and sitABC in biofilm-associated Staphylococcus epidermidis.

• Massonet C, Pintens V, Merckx R, Anné J, Lammertyn E, Van Eldere J.
  BMC Microbiol. 2006 Dec 19;6:103.

The type II signal peptidase of Legionella pneumophila.

• Geukens N, De Buck E, Meyen E, Maes L, Vranckx L, Van Mellaert L, Anné J, Lammertyn E.
  Res Microbiol. 2006 Nov;157(9):836-41.

Evaluation of TatABC overproduction on Tat- and Sec-dependent protein secretion in Streptomyces lividans.

• De Keersmaeker S, Vrancken K, Van Mellaert L, Lammertyn E, Anné J, Geukens N.
  Arch Microbiol. 2006 Dec;186(6):507-12

The use of clostridial spores for cancer treatment.

• Barbé S, Van Mellaert L, Anné J.
  J Appl Microbiol. 2006 Sep;101(3):571-8. Review.

Detection and quantification of Legionella pneumophila in water samples using competitive PCR.

• Declerck P, Behets J, Lammertyn E, Lebeau I, Anné J, Ollevier F.
  Can J Microbiol. 2006 Jun;52(6):584-90.

Compensatory effect of the minor Streptomyces lividans type I signal peptidases on the SipY major signal peptidase deficiency as determined by extracellular proteome analysis.

• Escutia MR, Val G, Palacín A, Geukens N, Anné J, Mellado RP.
  Proteomics. 2006 Jul;6(14):4137-46.

Surface plasmon resonance-based interaction studies reveal competition of Streptomyces lividans type I signal peptidases for binding preproteins.

• Geukens N, Rao C V S, Mellado RP, Frederix F, Reekmans G, De Keersmaeker S, Vrancken K, Bonroy K, Van Mellaert L, Lammertyn E, Anné J.
  Microbiology. 2006 May;152(Pt 5):1441-50.

Clostridium spores as anti-tumour agents.

• Van Mellaert L, Barbé S, Anné J.
  Trends Microbiol. 2006 Apr;14(4):190-6.

Functional large-scale production of a novel Jonesia sp. xyloglucanase by heterologous secretion from Streptomyces lividans.

• Sianidis G, Pozidis C, Becker F, Vrancken K, Sjoeholm C, Karamanou S, Takamiya-Wik M, van Mellaert L, Schaefer T, Anné J, Economou A.
  J Biotechnol. 2006 Feb 24;121(4):498-507.

Inactivation of the 20S proteasome in Streptomyces lividans and its influence on the production of heterologous proteins.

• Hong B, Wang L, Lammertyn E, Geukens N, Van Mellaert L, Li Y, Anné J.
  Microbiology. 2005 Sep;151(Pt 9):3137-45.

Functional analysis of TatA and TatB in Streptomyces lividans.

• De Keersmaeker S, Van Mellaert L, Lammertyn E, Vrancken K, Anné J, Geukens N.
  Biochem Biophys Res Commun. 2005 Sep 30;335(3):973-82.

Legionella pneumophila Philadelphia-1 tatB and tatC affect intracellular replication and biofilm formation.

• De Buck E, Maes L, Meyen E, Van Mellaert L, Geukens N, Anné J, Lammertyn E.
  Biochem Biophys Res Commun. 2005 Jun 17;331(4):1413-20.

Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment.

• Barbé S, Van Mellaert L, Theys J, Geukens N, Lammertyn E, Lambin P, Anné J.
  FEMS Microbiol Lett. 2005 May 1;246(1):67-73.

Structural organization of the twin-arginine translocation system in Streptomyces lividans.

• De Keersmaeker S, Van Mellaert L, Schaerlaekens K, Van Dessel W, Vrancken K, Lammertyn E, Anné J, Geukens N.
  FEBS Lett. 2005 Jan 31;579(3):797-802.

First proteomic analysis of Legionella pneumophila based on its developing genome sequence.

• Lebeau I, Lammertyn E, De Buck E, Maes L, Geukens N, Van Mellaert L, Arckens L, Anné J, Clerens S.
  Res Microbiol. 2005 Jan-Feb;156(1):119-29.

Complete genomic nucleotide sequence and analysis of the temperate bacteriophage VWB.

• Van Dessel W, Van Mellaert L, Liesegang H, Raasch C, De Keersmaeker S, Geukens N, Lammertyn E, Streit W, Anné J.
  Virology. 2005 Jan 20;331(2):325-37.

Clostridium-mediated transfer system of therapeutic proteins to solid tumors: increased heterologous protein production.

• Barbé S, Van Mellaert L, Anné J.
  Commun Agric Appl Biol Sci. 2004;69(2):49-52.

Type I signal peptidases of Gram-positive bacteria.

• van Roosmalen ML, Geukens N, Jongbloed JD, Tjalsma H, Dubois JY, Bron S, van Dijl JM, Anné J.
  Biochim Biophys Acta. 2004 Nov 11;1694(1-3):279-97. Review

Protein secretion in Legionella pneumophila and its relation to virulence.

• Lammertyn E, Anné J.
  FEMS Microbiol Lett. 2004 Sep 15;238(2):273-9. Review.

The use of the cMyc epitope tag can be problematic for protein detection in Legionella pneumophila.

• De Buck E, Lebeau I, Van Mellaert L, Geukens N, Anné J, Lammertyn E.
  J Microbiol Methods. 2004 Oct;59(1):131-4.

Comparison of the Sec and Tat secretion pathways for heterologous protein production by Streptomyces lividans.

• Schaerlaekens K, Lammertyn E, Geukens N, De Keersmaeker S, Anné J, Van Mellaert L.
  J Biotechnol. 2004 Sep 9;112(3):279-88.

Isolation of high quality RNA from Streptomyces.

• Van Dessel W., L. Van Mellaert, N. Geukens, E. Lammertyn & J. Anné.
  Journal of Microbiological Methods. 2004

Molecular and functional characterisation of type I signal peptidase from Legionella pneumophila.

• Lammertyn, E., L. Van Mellaert, E. Meyen, I. Lebeau, E. De Buck, J. Anné & N. Geukens.
  Microbiology (SGM). 2004 150: 1475-1483.  

A putative twin-arginine translocation pathway in Legionella pneumophila.

• De Buck, E., Lebeau, I., Maes, L., Geukens, N., Meyen, E., Van Mellaert, L., Anné, J. & Lammertyn, E.
  Biochem Biophys Res Commun. 2004 Apr 30;317(2):654-61.

Analysis of type I signal peptidase affinity and specificity for preprotein substrates.

• Geukens, N., F. Frederix, G. Reekmans, E. Lammertyn, L. Van Mellaert, W. Dehaen, G. Maes & J. Anné.
  Biochem. Biophys. Res. Comm. 2004: 314, 459-467.

The importance of the Tat-dependent protein secretion pathway in Streptomyces as revealed by phenotypic changes in tat deletion mutants and genome analysis.

• Schaerlaekens K., Van Mellaert L., Lammertyn E., Geukens N. & Anné J. 2004.
  Microbiology, 150: 21-31.

Leader peptidases with an emphasis on Gram positive bacteria.

• van Roosmalen M.L., Geukens N., Jongbloed J.D.H., Tjalsma H., Dubois J.Y.F., Bron S., van Dijl J.M., and Anné J. Biochimica et Biophysica Acta.

Non-invasive (19)F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours.

• Dresselaers T, Theys J, Nuyts S, Wouters B, De Bruijn E, Anné J, Lambin P, Van Hecke P, Landuyt W.
  Br J Cancer. 2003 Nov 3;89(9):1796-801.

Expression of biologically active human tumor necrosis factor beta by Streptomyces lividans.

• Hong B., Li Y, Van Mellaert G & Anné J. 2003.
  Yi Chuan XueBao, 30, 209-214

Tumour-specific gene delivery using genetically engineered bacteria. 

• Theys J., Barbé S., Landuyt W., Nuyts S., Van Mellaert L., Wouters B., Anné J. & Lambin P.
  Current Gene Therapy Jun 2003;3(3):207-221.

Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions.  

• Ismail MS, Wynendaele W, Aerts JL, Paridaens R, Van Mellaert L, Anne J, Gaafar R, Shakankiry N, Khaled HM, Christiaens MR, Omar S, Vandekerckhove P, Van Oosterom AT.
  Annals of Oncology, Aug 2003;14(8):1241-1245.

Improved PCR-based method for the direct screening of Streptomyces transformants.  

• Van Dessel W., Van Mellaert L., Geukens N. & Anné J. 2003.
  Journal of Microbiological Methods. vol 53/3 pp 401 - 403.

Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella Typhimurium.                    

• Mei S., Theys J., Landuyt W., Anné J. & Lambin P. 2002.
  Anticancer Res. 2002 Nov-Dec;22(6A):3261-3266.

Evidence for SipY as the major type I signal peptidase of Streptomyces lividans.

• Palacín A., Parro V, Geukens N., Anné J. & Mellado R.P. 2002.
  J. Bacteriol. 184, 4875-4880.

Clostridium spores for tumor-specific delivery of drugs.

• Nuyts S., Van Mellaert L, Theys J, Landuyt W., Lambin P. & Anné J. 2002.
  Anti-Cancer Drugs 13(2), 115-125.

Physical requirements for the in vitro processing of the Streptomyces lividans signal peptidases.

• Geukens N., Lammertyn E., Van Mellaert L., Engelborghs Y., Mellado R.P. & Anné J. 2002.
  J. Biotechnology 96, 79-91.

Anaerobic bacteria as a tumor-specific delivery system of therapeutic proteins.

• Theys, J., Landuyt, W., Nuyts, S., Van Mellaert, L., Lambin, P. & Anné, J. 2001.
  Cancer Detect. Prev. 25, 548-557.

Evidence or a functional twin-arginine mediated secretion pathway in Streptomyces.

• Schaerlaekens T., Schierova M. Van Mellaert L., Lammertyn E., Geukens N. & Anné J. 2001.
  J. Bacteriol. 183, 6727-6732.

Modification of radio-inducibility of Clostridium promoters by insertion or deletion of the Cheo box.

• Nuyts S., L. Van Mellaert, S. Barbé, J. Theys, W. Landuyt, E. Bosmans, P. Lambin & J. Anné. 2001.
  Appl. Envir. Microbiol., 67, 4464-4470.

Evidence of substrate preference between the Streptomyces lividans type I signal peptidases.

• Geukens N., Parro V., Rivas L.R., Mellado R.P.& Anné J. (2001)
  Arch. Microbiol. 176(5), 377-80.

Radioresponse recA promotes significantly increases TNFa production in recombinant clostridia after 2 Gy irradiation.

• Nuyts, S., Van Mellaert, L., Theys, J., Landuyt, W., Bosmans, E., Anné, J. & Lambin, P. 2001.
  Gene Therapy. 8,1197-201.

Membrane topology of the Streptomyces lividans type I signal peptidases.

• N. Geukens, E. Lammertyn, L. Van Mellaert, S. Schacht, K. Schaerlaekens, V. Parro, S. Bron, Y. Engelborghs, R. Mellado & J. Anné 2001.
  J. Bacteriology, 183, 4752-4760

Efficient isolation of total RNA from Clostridium without DNA contamination.

• S. Nuyts, L. Van Mellaert, P. Lambin, J. Anné. 2001.
  J. Microbiol Methods 44, 235-238

Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum.

• Theys, J., Nuyts, S., Landuyt, W., Van Mellaert, L., de Bruijn, E., Anné, J. & Lambin, P. 2001.
  Cancer Gene Ther. 8, 247-297.

The use of radio-induced bacterial promoters in anaerobic conditions: a means to control gene-expression in Clostridium-mediated therapy for cancer.

• Nuyts, S., Van Mellaert, L., Theys, J., Landuyt, W., Lambin, P. & Anné, J. 2001.
  Radiation Res. 155, 716-723.

Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters.

• Nuyts, S., Theys, J., Landuyt, W., Van Mellaert, L., Lambin, P. & Anné, J. 2001.
  Anticancer Res. 21(2) 857-862.

In vivo anti-tumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.

• Landuyt, W., Ahmed, B., Nuyts, S., Theys, J., Op de Beeck, M., Tech, A., Reijnders, A., Anné, J., van Oosterom, A., Van den Bogaert, W. & Lambin, P. 2001.
  Int J Radiat Oncol Biol Phys 2001 Feb 1; 49(2):443-450

Protein secretion biotechnology using Streptomyces lividans: large-scale production of functional trimeric tumor necrosis factor a.

• C. Pozidis, E. Lammertyn, A. S. Politou, J. Anné, A. S. Tsiftsoglou, G. Sianidis & A. Economou. 2001.
  Biotechnology and Bioengineering, 72, 611-619.

Vascular targeting of solid tumours - a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas.

• W. Landuyt, O. Verdoes, D.O. Darius, M. Drijkoningen, S. Nuyts, J. Theys, L. Stockx, W. Wynendaele, J.F. Fowler, G. Maleux, W. Van den Bogaert, J. Anné, A. van Oosterom, P. Lambin. 2000.
  European Journal of Cancer, 36, 1833-1843.

The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase.

• Lambin, P., Nuyts, S., Landuyt, W., Theys, J., de Bruijn, E., Anné, J., Van Mellaert, L. & Fowler, J. 2000.
  Int. J. Radiat. Biol. 76, 285-293.

Effect of TNP-470 (AGM-1470) on the growth of rat rhabdomyosarcoma tumours of different growth.

• W. Landuyt, J. Theys, S. Nuyts, M. Drijkoningen, J. Fowler, A. Reijnders, S. Liekens, J. Neyts, E. de Bruijn, J. Anné & P. Lambin. 2001.
  Cancer Invest. 19, 35-40

The HIV-1 reverse transcription (RT) process as target for RT inhibitors.

• H. Jonckheere, J. Anné & E. De Clercq. 2000.
  Medicinal Research Reviews, 20 (2), 129-154.

Fidelity analysis of HIV-1 reverse transcriptase mutants with an altered amino acid sequence at residue Leu 74, Gln 89, Tyr 183 and Tyr 115.

• H. Jonckheere, E. De Clercq & J. Anné. 2000.
  Eur. J. Biochem. 267, (9), 2658-2665.

Protein secretion in Gram-positive bacteria with high GC-content.

• L. Van Mellaert & J. Anné. 1999.
  Recent Research Developments Microbiology, 3, 425-440

Clostridia: special heterologous expression systems for prokaryotic and eukaryotic proteins

• L. Van Mellaert, S. Barbé, J. Theys, W. Landuyt, P. Lambin & J. Anné. 2004.
  in "Handbook on Clostridia". CRC Press, in press

Tumor-specific gene therapy delivery with engineered bacteria. In press

• J. Theys, S. Barbé, W. Landuyt, S. Nuyts, L. Van Mellaert, B. Wouters, J. Anné & P. Lambin. 2004.

"Cancer Gene Therapy" Bacterial Systems.

• P. Lambin, Jan Theys, Sandra Nuyts, Willy Landuyt, & J. Anné. 2003.
  Editors: David T. Curiel, M.D. and Joanne T. Douglas, Ph.D. Humana Press, Inc. in press

Clostridium-mediated transfer of therapeutic proteins to solid tumors: an alternative to gene-therapy approaches.

• P. Lambin, J. Theys, S. Nuyts, W. Landuyt, L. Van Mellaert & J. Anné. 2002.
  In "Vector targeting for therapeutic gene delivery". (David Curiel and Joanne Douglas, Editors). Wiley publ. pp. 527-546.

Gram-positive bacteria for the heterologous production of biopharmaceutical compounds.

• L. Van Mellaert & J. Anné. 2001.
  In "Novel Frontiers in the Production of Compounds for Biomedical Use, Vol. I" A. Van Broekhoven, F. Shapiro & J. Anné, eds.) Kluwer Academic publishers. pp. 277-300.

Recombinant clostridia in Cancer Therapy.

• N. Minton, M. Brown, P. Lambin & J. Anné. 2001.
  In Clostridia - Biotechnology and Medical Applications" Wiley (ed. H. Bahl & P. Dürre)